Physician profile
Robert Friedman
NPI 1336161157
$3,575.38
in general payments reported to CMS, 2019-2025
27 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $403 · 2021: $746 · 2022: $504 · 2023: $267 · 2024: $637 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.98 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $596.13 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Sight Sciences, INC. | $396.05 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $294.29 | 2020-2021 | |
| Abbvie INC. | $245.59 | 2023-2024 | |
| Biotissue Holdings INC. | $233.28 | 2022-2024 | |
| Allergan, INC. | $227.44 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $139.70 | 2022-2025 | Envista Aspire Iol, Xiidra, Miebo |
| Thea Pharma INC. | $128.35 | 2023-2025 | Iyuzeh |
| Omeros Corporation | $125.00 | 2019 | |
| Glaukos Corporation | $116.83 | 2020-2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $105.65 | 2024-2025 | Xdemvy |
| Ivantis, INC | $105.26 | 2021 | |
| Astellas Pharma US INC | $102.44 | 2024-2025 | Izervay |
| Oyster Point Pharma, INC. | $101.19 | 2024-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $94.24 | 2021-2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92.00 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec, INC. | $85.76 | 2020 | |
| Rxsight INC | $78.13 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $65.14 | 2021-2024 | Tecnis Iol |
| Kala Pharmaceuticals, INC. | $62.58 | 2021 | |
| New World Medical,INC. | $56.13 | 2022 | |
| Apellis Pharmaceuticals, INC. | $27.48 | 2023 | Syfovre |
| Aerie Pharmaceuticals, INC. | $24.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $20.40 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $17.32 | 2020 | |
| Horizon Therapeutics Plc | $15.60 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.